Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial. A Phase IV Open-Label Trial Using 150,300, 600 mg/Day Of Pregabalin.
Phase of Trial: Phase IV
Latest Information Update: 04 Feb 2011
At a glance
- Drugs Pregabalin (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Acronyms PREPS
- Sponsors Pfizer
- 27 Oct 2009 Actual patient number (136) added as reported by ClinicalTrials.gov.
- 09 Jun 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 20 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.